Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Vaccine Production01:23

Vaccine Production

144
Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...
144
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

1.3K
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
1.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The rationale for universal use of a prophylactic Epstein-Barr virus vaccine.

Virology·2026
Same author

Primary Epstein-Barr virus infection in preadolescent children: A prospective study.

Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology·2025
Same author

Epstein-Barr virus (EBV) infection and its sequelae in the immunocompetent host.

Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology·2025
Same author

Infectious Mononucleosis.

Current topics in microbiology and immunology·2025
Same author

Valacyclovir or valganciclovir for cytomegalovirus prophylaxis: A randomized controlled trial in adult and pediatric kidney transplant recipients.

Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology·2024
Same author

Antivirals for COPD?

Chest·2023

Related Experiment Video

Updated: May 2, 2026

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant
08:52

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant

Published on: May 27, 2011

18.4K

Progress, prospects, and problems in Epstein-Barr virus vaccine development.

Henry H Balfour1

  • 1Department of Laboratory Medicine and Pathology, University of Minnesota Medical School, Minneapolis, MN 55455, United States; Department of Pediatrics, University of Minnesota Medical School, Minneapolis, MN 55455, United States.

Current Opinion in Virology
|March 18, 2014
PubMed
Summary

Developing an Epstein-Barr virus (EBV) vaccine faces challenges, including the need for better animal models and consensus on goals. Recent advocacy for a phase 3 trial offers hope for future licensure.

More Related Videos

Isolation and Quantification of Epstein-Barr Virus from the P3HR1 Cell Line
09:14

Isolation and Quantification of Epstein-Barr Virus from the P3HR1 Cell Line

Published on: September 28, 2022

4.1K
An Efficient and Simple Method to Establish NK and T Cell Lines from Patients with Chronic Active Epstein-Barr Virus Infection
09:43

An Efficient and Simple Method to Establish NK and T Cell Lines from Patients with Chronic Active Epstein-Barr Virus Infection

Published on: March 30, 2018

8.5K

Related Experiment Videos

Last Updated: May 2, 2026

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant
08:52

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant

Published on: May 27, 2011

18.4K
Isolation and Quantification of Epstein-Barr Virus from the P3HR1 Cell Line
09:14

Isolation and Quantification of Epstein-Barr Virus from the P3HR1 Cell Line

Published on: September 28, 2022

4.1K
An Efficient and Simple Method to Establish NK and T Cell Lines from Patients with Chronic Active Epstein-Barr Virus Infection
09:43

An Efficient and Simple Method to Establish NK and T Cell Lines from Patients with Chronic Active Epstein-Barr Virus Infection

Published on: March 30, 2018

8.5K

Area of Science:

  • Virology and Immunology
  • Vaccine Development

Background:

  • Epstein-Barr virus (EBV) causes numerous acute and chronic diseases, including cancers.
  • A prophylactic EBV vaccine could significantly reduce the global disease burden.
  • Existing EBV vaccine candidates require further study to establish safety and efficacy.

Purpose of the Study:

  • To review the challenges and progress in Epstein-Barr virus (EBV) vaccine development.
  • To highlight the need for a consensus on EBV vaccine objectives and the importance of a phase 3 trial.

Main Methods:

  • Review of existing literature and recent conference findings on EBV vaccine research.
  • Discussion of hurdles including animal models, adjuvants, and proprietary issues.

Main Results:

  • Several EBV vaccines have been tested in humans, but none have been adequately evaluated for safety and efficacy.
  • Key challenges include the lack of suitable animal models (besides primates), adjuvant selection, and defining vaccine goals.

Conclusions:

  • Recent emphasis on the global importance of an EBV vaccine and advocacy for a phase 3 trial are encouraging.
  • Further research is needed to overcome development hurdles and achieve EBV vaccine licensure.